Tech Company Financing Transactions
Thrive Earlier Detection Funding Round
Thrive Earlier Detection, operating out of Cambridge, secured $110 million from Third Rock Ventures, Biomatics Capital Partners and BlueCross BlueShield Venture Partners.
Transaction Overview
Company Name
Announced On
5/31/2019
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Series A
Investors
Proceeds Purpose
Financing Will Support Expanded Clinical Development to Enable Regulatory Approvals and Broad Reimbursement Access
Company Information
Company Status
Acquired or Merged
Industry
Healthcare IT
Mailing Address
38 Sidney St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease that will serve as the core of its integrated cancer information offering.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Daly
Chief Financial Officer
Isaac Ro
Chief Operating Officer
Christoph Lengauer
VP - Bus. Development
Matthew Franklin
VP - General Counsel
Dina Ciarimboli
VP - Human Resources
Semi Trotto
VP - Product Management
Geoff Otto
VP - R & D
Isaac Kinde
VP - Regulatory Affairs
Seema Bhan
Browse more venture capital transactions:
Prev: 5/31/2019: Swimlane venture capital transaction
Next: 5/31/2019: TFF Pharmaceuticals venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs